Sodium Channel Inhibitors Reduce DMPK mRNA and Protein-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sodium Channel Inhibitors Reduce DMPK mRNA and Protein

Published:2015-05-22 Issue:4 Volume:8 Page:298-304
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Witherspoon Luke¹²,O'Reilly Sean¹²,Hadwen Jeremiah¹²,Tasnim Nafisa¹²,MacKenzie Alex¹²,Farooq Faraz²³

Affiliation:

1. University of Ottawa; Ottawa Canada

2. Apoptosis Research Center; CHEO Research Institute; CHEO Ottawa Canada

3. Emirates College for Advance Education; Abu Dhabi UAE

Funder

Canadian Institutes of Health Research

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Reference24 articles.

1. Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome pathway;Vignaud;Neuromuscul Disord,2010

2. Microsatellite repeat instability and neurological disease;Brouwer;Bioessays,2009

3. Pathogenic mechanisms of myotonic dystrophy;Lee;Biochem Soc Trans,2009

4. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member;Brook;Cell,1992

5. The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy;Hunter;J Med Genet,1992

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms and therapeutic strategies for neuromuscular diseases;Cellular and Molecular Life Sciences;2024-04-28

2. The myotonic dystrophy type 1 drug development pipeline: 2022 edition;Drug Discovery Today;2023-03

3. Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy;Molecular Therapy - Nucleic Acids;2021-12

4. Myotonic dystrophy type 1 drug development: A pipeline toward the market;DRUG DISCOV TODAY;2021

5. Myotonic dystrophy type 1 drug development: A pipeline toward the market;Drug Discovery Today;2021-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3